FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014694744> ?p ?o ?g. }

• W2014694744 endingPage "8428" @default.
• W2014694744 startingPage "8417" @default.
• W2014694744 abstract "We conducted a phase I/II randomized placebo-controlled trial with the aim of exploring whether priming with a low intradermal dose of a multiclade, multigene HIV-1 DNA vaccine could improve the immunogenicity of the same vaccine given intramuscularly prior to boosting with a heterologous HIV-1 MVA among healthy adults in Dar es Salaam, Tanzania.Sixty HIV-uninfected volunteers were randomized to receive DNA plasmid vaccine 1mg intradermally (id), n=20, or 3.8mg intramuscularly (im), n=20, or placebo, n=20, using a needle-free injection device. DNA plasmids encoding HIV-1 genes gp160 subtype A, B, C; rev B; p17/p24 gag A, B and Rtmut B were given at weeks 0, 4 and 12. Recombinant MVA (10(8)pfu) expressing HIV-1 Env, Gag, Pol of CRF01_AE or placebo was administered im at month 9 and 21.The vaccines were well tolerated. Two weeks after the third HIV-DNA injection, 22/38 (58%) vaccinees had IFN-γ ELISpot responses to Gag. Two weeks after the first HIV-MVA boost all 35 (100%) vaccinees responded to Gag and 31 (89%) to Env. Two to four weeks after the second HIV-MVA boost, 28/29 (97%) vaccinees had IFN-γ ELISpot responses, 27 (93%) to Gag and 23 (79%) to Env. The id-primed recipients had significantly higher responses to Env than im recipients. Intracellular cytokine staining for Gag-specific IFN-γ/IL-2 production showed both CD8(+) and CD4(+) T cell responses. All vaccinees had HIV-specific lymphoproliferative responses. All vaccinees reacted in diagnostic HIV serological tests and 26/29 (90%) had antibodies against gp160 after the second HIV-MVA boost. Furthermore, while all of 29 vaccinee sera were negative for neutralizing antibodies against clade B, C and CRF01_AE pseudoviruses in the TZM-bl neutralization assay, in a PBMC assay, the response rate ranged from 31% to 83% positives, depending upon the clade B or CRF01_AE virus tested.This vaccine approach is safe and highly immunogenic. Low dose, id HIV-DNA priming elicited higher and broader cell-mediated immune responses to Env after HIV-MVA boost compared to a higher HIV-DNA priming dose given im. Three HIV-DNA priming immunizations followed by two HIV-MVA boosts efficiently induced Env-antibody responses." @default.
• W2014694744 created "2016-06-24" @default.
• W2014694744 creator A5001134590 @default.
• W2014694744 creator A5003760687 @default.
• W2014694744 creator A5004527390 @default.
• W2014694744 creator A5019647556 @default.
• W2014694744 creator A5030596607 @default.
• W2014694744 creator A5031532217 @default.
• W2014694744 creator A5041344472 @default.
• W2014694744 creator A5045642851 @default.
• W2014694744 creator A5048004508 @default.
• W2014694744 creator A5050241874 @default.
• W2014694744 creator A5056805876 @default.
• W2014694744 creator A5057965152 @default.
• W2014694744 creator A5058685878 @default.
• W2014694744 creator A5061857469 @default.
• W2014694744 creator A5073981579 @default.
• W2014694744 creator A5074775871 @default.
• W2014694744 creator A5076100669 @default.
• W2014694744 creator A5076820552 @default.
• W2014694744 creator A5077646556 @default.
• W2014694744 creator A5079175803 @default.
• W2014694744 creator A5089233990 @default.
• W2014694744 date "2011-10-01" @default.
• W2014694744 modified "2023-10-15" @default.
• W2014694744 title "Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania" @default.
• W2014694744 cites W1587830797 @default.
• W2014694744 cites W1964407118 @default.
• W2014694744 cites W1965501933 @default.
• W2014694744 cites W1966882334 @default.
• W2014694744 cites W1969251048 @default.
• W2014694744 cites W1970267929 @default.
• W2014694744 cites W1970675177 @default.
• W2014694744 cites W1976664080 @default.
• W2014694744 cites W1989240299 @default.
• W2014694744 cites W1995300440 @default.
• W2014694744 cites W2014071844 @default.
• W2014694744 cites W2018792628 @default.
• W2014694744 cites W2019041261 @default.
• W2014694744 cites W2020857934 @default.
• W2014694744 cites W2028352208 @default.
• W2014694744 cites W2032104932 @default.
• W2014694744 cites W2035134577 @default.
• W2014694744 cites W2038114373 @default.
• W2014694744 cites W2038474754 @default.
• W2014694744 cites W2051052747 @default.
• W2014694744 cites W2053035745 @default.
• W2014694744 cites W2057487103 @default.
• W2014694744 cites W2061339484 @default.
• W2014694744 cites W2075340091 @default.
• W2014694744 cites W2083008217 @default.
• W2014694744 cites W2087337413 @default.
• W2014694744 cites W2096904495 @default.
• W2014694744 cites W2097771941 @default.
• W2014694744 cites W2105323221 @default.
• W2014694744 cites W2105809563 @default.
• W2014694744 cites W2107683840 @default.
• W2014694744 cites W2109238906 @default.
• W2014694744 cites W2125302207 @default.
• W2014694744 cites W2126851513 @default.
• W2014694744 cites W2130202391 @default.
• W2014694744 cites W2132014099 @default.
• W2014694744 cites W2138957964 @default.
• W2014694744 cites W2149024166 @default.
• W2014694744 cites W2151026229 @default.
• W2014694744 cites W2152048324 @default.
• W2014694744 cites W2152640863 @default.
• W2014694744 cites W2153670011 @default.
• W2014694744 cites W2155487723 @default.
• W2014694744 cites W2157210912 @default.
• W2014694744 cites W2160663355 @default.
• W2014694744 cites W2161157573 @default.
• W2014694744 cites W2171139716 @default.
• W2014694744 cites W2171987627 @default.
• W2014694744 cites W2172153375 @default.
• W2014694744 cites W4236423954 @default.
• W2014694744 doi "https://doi.org/10.1016/j.vaccine.2011.08.001" @default.
• W2014694744 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4795940" @default.
• W2014694744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21864626" @default.
• W2014694744 hasPublicationYear "2011" @default.
• W2014694744 type Work @default.
• W2014694744 sameAs 2014694744 @default.
• W2014694744 citedByCount "101" @default.
• W2014694744 countsByYear W20146947442012 @default.
• W2014694744 countsByYear W20146947442013 @default.
• W2014694744 countsByYear W20146947442014 @default.
• W2014694744 countsByYear W20146947442015 @default.
• W2014694744 countsByYear W20146947442016 @default.
• W2014694744 countsByYear W20146947442017 @default.
• W2014694744 countsByYear W20146947442018 @default.
• W2014694744 countsByYear W20146947442019 @default.
• W2014694744 countsByYear W20146947442020 @default.
• W2014694744 countsByYear W20146947442021 @default.
• W2014694744 countsByYear W20146947442022 @default.
• W2014694744 countsByYear W20146947442023 @default.
• W2014694744 crossrefType "journal-article" @default.
• W2014694744 hasAuthorship W2014694744A5001134590 @default.
• W2014694744 hasAuthorship W2014694744A5003760687 @default.

• next